RAD51D and ovarian carcinoma: Moreover, a recent meta-analysis provided evidence supporting the pathogenicity of BRIP1, RAD51C, and RAD51D mutations in relation to ovarian cancer, cumulatively contributing to ~2% of ovarian cancer cases [7].